Myomo

MYO

Market cap $30.8M

Myomo, Inc. (MYO) Q4 2025 Earnings Call Transcript

Myomo, Inc. (MYO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.01 per share a year ago.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. “We delivered 2025 revenue at the midpoint of our updated guidance range with record fourth quarter revenues from the U.S. orthotics and prosthetics ("O&P") and Int.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become eff.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business upd.

Myomo, Inc. ( MYO ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Paul Gudonis - President, CEO & Chairman David Henry - Chief Financial Officer Conference Call Participants Tirth Patel Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Scott Henry - Alliance Global Partners, Research Division Anthony Vendetti - Maxim Group LLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Good day, and welcome to the Myomo Third Quarter 2025 Financial Results Conference Call.

Myomo, Inc. (MYO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.03 per share a year ago.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025. “Third quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics ("O&P") revenues at record levels. Revenue.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter of 2025 on Monday, November 10, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questio.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer, and David Henry, chief financial officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace.